16 completed, 3 terminated, 1 active not recruiting, 1 unknown. 22 Phase 1, 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 22 | Completed 16, Terminated 3, Active not recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 11 | Completed 7, Terminated 2, Unknown 1, Withdrawn 1 |
Follow ProMune: new trials by email Literature Review of ProMune trials Research Report on ProMune
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes Aluminum Hydroxide Suspension, Boost-2867, CpG 7909 - COVID-19 | Phase 1 | Active not recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 140 | 2025-12-05 | 2026-06-23 |
| Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram-negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant CPG 7909, J5-OMP Vaccine, Placebo - Bacterial Sepsis | Phase 1 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2011-11-01 | 2014-01-31 |
| A Study to Assess Safety, Immunogenicity and Parasite Growth Inhibition of an Asexual Blood Stage Vaccine for P. Falciparum Malaria AMA1-C1/Alhydrogel® + CPG 7909 - Malaria | Phase 1 / Phase 2 | Completed | University of Oxford | 8 | 2010-01-01 | 2015-05-28 |
| Phase I Study of the Safety and Immunogenicity of BSAM-2/Alhydrogel +CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria in Adults in the US and Mali BSAM2/Alhydrogel + CPG 7909 - Malaria | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 154 | 2009-04-23 | 2019-12-17 |
| Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Peptide vaccine, GM-CSF, PF3512676 - Intraocular Melanoma, Malignant Conjunctival Neoplasm | Phase 1 | Completed | Ahmad Tarhini | 22 | 2008-10-01 | 2017-06-22 |
| Malaria Vaccine for Children in Mali AMA1-C1/Alhydrogel plus CPG 7909 - Malaria, Malaria Infection | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 200 | 2008-08-11 | 2017-07-02 |
| Immune Response to Toll-Like Receptor 9-Agonist Adjuvanted Pneumococcal Vaccination in HIV Infected Adults Pneumococcal vaccines + CPG 7909, Pneumococcal vaccines - HIV Infections | Phase 1 / Phase 2 | Completed | University of Aarhus | 97 | 2008-01-01 | 2009-01-21 |
| Safety, Tolerability, Immunogenicity And CPG Dosage Finding Study of Novartis CpG Adjuvanted Flu Vaccine Subunit influenza vaccine, Adjuvanted influenza vaccine, Adjuvanted influenza vaccine combined with CpG7909 - Influenza Infection | Phase 1 | Completed | Novartis | 60 | 2007-10-01 | 2009-11-05 |
| Phase I Study of AMA1-C1/Alhydrogel® (Registered Trademark) + CPG 7909 Malaria Vaccine AMA1-C1/Alhydrogel + CPG 7909 (Saline), AMA1-C1/Alhydrogel + CPG 7909 (Phosphate), AMA1-C1/Alhydrogel + CPG 7909 - Malaria | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 300 | 2007-01-23 | 2017-07-02 |
| PhaseⅠ/Ⅱ Study of URLC10-177 and TTK-567 Peptide Vaccine Combined With CpG7909 in Patients With Esophageal Cancer URLC10-177, TTK-567, CpG-7909 - Esophageal Cancer | Phase 1 / Phase 2 | Unknown | Wakayama Medical University | 29 | 2006-11-01 | 2010-09-09 |
| Safety of and Immune Response to a Malaria Vaccine (MSP1 42-C1) With or Without CPG 7909 Adjuvant MSP1 42-C1/Alhydrogel, CPG 7909 - Malaria | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 60 | 2006-03-01 | 2008-01-21 |
| Improving the Efficacy of Experimental Malaria Vaccine AMA1-C1/Alhydrogel® (Registered Trademark) AMA1-C1/Alhydrogel + CpG 7909 - Healthy Volunteer, HV | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-03-08 | 2017-07-02 | |
| Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides. CPG 7909 - Mycosis Fungoides | Phase 1 / Phase 2 | Withdrawn | Stanford University | 2005-03-01 | 2016-12-01 | |
| Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma MAGE-3.A1 peptide and CpG 7909 - Malignant Melanoma | Phase 1 / Phase 2 | Terminated | Ludwig Institute for Cancer Research | 1 | 2005-01-12 | 2022-10-07 |
| Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma 8 HLA-A2-restricted peptides and Montanide ISA51, 8 HLA-A2-restricted peptides and CpG 7909 - Malignant Melanoma | Phase 1 / Phase 2 | Terminated | Ludwig Institute for Cancer Research | 23 | 2005-01-01 | 2022-10-10 |
| Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma Agatolimod Sodium, Indium In-111 Ibritumomab Tiuxetan, Laboratory Biomarker Analysis - Adult Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 1 / Phase 2 | Completed | Mayo Clinic | 38 | 2004-10-01 | 2016-02-04 |
| CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas CPG 7909 - Non-Hodgkin Lymphoma, Mycosis Fungoides | Phase 1 / Phase 2 | Completed | Ronald Levy | 30 | 2004-07-01 | 2014-08-01 |
| A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated CpG 7909 - Chronic Lymphocytic Leukemia | Phase 1 | Completed | University of Iowa | 41 | 2004-07-01 | 2017-02-06 |
| A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer. NY-ESO-1b peptide plus CpG 7909 and Montanide® ISA-51 - Cancer, Neoplasm | Phase 1 | Completed | Ludwig Institute for Cancer Research | 14 | 2003-09-03 | 2022-10-10 |
| CPG 7909 in Patients With Cutaneous T-Cell Lymphoma PF-3512676 - Lymphoma, T-Cell, Cutaneous | Phase 1 / Phase 2 | Completed | Pfizer | 42 | 2003-01-01 | 2009-02-12 |
Showing 20 of 22. Sign in to see all of them.
Malaria (5) · Malaria, Falciparum (3) · Melanoma (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Mycosis Fungoides (2) · Neoplasms (2) · COVID-19 (1) · Carcinoma (1) · Carcinoma, Renal Cell (1) · Coronavirus Infections (1) · Esophageal Neoplasms (1) · HIV Infections (1) · Lymphoma, B-Cell, Marginal Zone (1)
National Institute of Allergy and Infectious Diseases (NIAID) (7) · Ludwig Institute for Cancer Research (3) · Pfizer (3) · Ahmad Tarhini (1) · Mayo Clinic (1) · Novartis (1) · Ronald Levy (1) · Stanford University (1) · University of Aarhus (1) · University of Iowa (1) · University of Oxford (1) · Wakayama Medical University (1)
United States (11) · Belgium (2) · Mali (2) · Denmark (1) · Germany (1) · Japan (1) · Switzerland (1) · United Kingdom (1)
Ronald Levy (2) · Adrian VS Hill, D.Phil, FRCP (1) · Ahmad A. Tarhini, MD, MS (1) · Anna Durbin, MD (1) · Brian Link, MD (1) · Clive Zent, M.D. (1) · Harold Burstein, M.D., Ph.D. (1) · Lars Ostergaard, MD,PhD,DmSC (1) · Nasser K Altorki, MD (1) · Nicolas VanBaren, MD (1) · Nicolas van Baren, MD (1) · Ole Sogaard, MD (1) · Ruth D Ellis, M.D. (1)
PMID 22045986, PMID 19728336, PMID 20107498, PMID 20504165, PMID 20697067, PMID 20874827, PMID 20888065, PMID 21799809, PMID 22495394, PMID 22854665, PMID 23056238, PMID 26514420, PMID 32632956
P30CA015083 (1)